Key result
Upcoming RCT tests Guipi Mixture plus metoprolol against placebo for reducing PVCs.
Why the study?
Metoprolol is effective for premature ventricular contractions but has limited efficacy and potential adverse effects, prompting evaluation of combining it with Guipi Mixture.
Does Guipi Mixture plus metoprolol reduce 24 h PVC count in patients with premature ventricular contractions (heart-spleen deficiency syndrome)?
RCT (n=200)
Double-blind
1:1
Yes
Does Guipi Mixture plus metoprolol reduce 24 h PVC count in patients with premature ventricular contractions (heart-spleen deficiency syndrome)?
This study protocol outlines a randomized trial to evaluate whether adding Guipi Mixture to metoprolol reduces premature ventricular contractions in patients with heart-spleen deficiency syndrome.
Answers are grounded in this paper and cite their sources.
Guipi Mixture plus metoprolol may broaden PVC treatment options; extends randomized evidence for TCM adjuncts in arrhythmia care.
Introduction Premature ventricular contractions (PVCs) are a common arrhythmia. Long-term frequent PVCs may contribute to tachycardia-induced cardiomyopathy, exacerbate angina, or trigger more severe ventricular arrhythmias, increasing cardiovascular risk. Current Western guidelines recommend pharmacotherapy or catheter ablation, with conservative drug therapy (e.g., lidocaine, propafenone, metoprolol, amiodarone, verapamil) remaining the mainstay. Metoprolol tartrate, a first-line drug, is effective for PVCs but has single targets, limited efficacy, and potential long-term cardiovascular adverse effects. Traditional Chinese Medicine (TCM) offers high efficacy and low toxicity. Guipi Mixture, a Chinese patent medicine for heart-spleen deficiency syndrome, combined with Western medicine may overcome these limitations. This study evaluates the efficacy and safety of Guipi Mixture plus metoprolol for PVCs (heart-spleen deficiency syndrome). Methods This is a randomized, double-blind, placebo-controlled, multicenter trial. Across 18 centers, 200 eligible subjects will be randomized (1:1) to intervention (Guipi Mixture + metoprolol) or control (Guipi Mixture placebo + metoprolol). The 12-week trial includes a 2-week screening, 2-week run-in, and 8-week treatment period. The primary outcome is the absolute change in 24 h PVC count from baseline to week 8 measured by ambulatory ECG (AECG). Secondary outcomes include responder rate (based on PVC reduction), SF-36 quality of life, PSQI sleep quality, TCM syndrome score, and ECG indicators. Adverse events will be recorded throughout the trial. Discussion This study will provide evidence on the efficacy and safety of Guipi Mixture for PVCs (heart-spleen deficiency syndrome) and explore its impact on patients’ quality of life. Clinical Trial Registration http://itmctr.ccebtcm.org.cn/ , identifier ITMCTR2025001333.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) conducted an RCT in Premature ventricular contractions (heart-spleen deficiency syndrome) (n=200). Guipi Mixture vs. Placebo (plus metoprolol 12.5 mg once daily) was evaluated on Absolute change in 24 h PVC count from baseline to week 8. This study protocol describes a planned randomized controlled trial to evaluate the efficacy and safety of Guipi Mixture combined with metoprolol for treating premature ventricular contractions.
Synapse has enriched 10 related papers. Consider them for comparative context: